Rockefeller Capital Management L.P. boosted its stake in Agilent Technologies Inc (NYSE:A) by 29.9% in the 4th quarter, Holdings Channel reports. The firm owned 2,635 shares of the medical research company’s stock after purchasing an additional 606 shares during the period. Rockefeller Capital Management L.P.’s holdings in Agilent Technologies were worth $225,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in A. BlackRock Inc. increased its position in Agilent Technologies by 0.7% during the second quarter. BlackRock Inc. now owns 25,137,175 shares of the medical research company’s stock worth $1,876,994,000 after buying an additional 178,265 shares during the last quarter. Dupont Capital Management Corp boosted its position in shares of Agilent Technologies by 281.6% in the 3rd quarter. Dupont Capital Management Corp now owns 30,343 shares of the medical research company’s stock worth $2,325,000 after purchasing an additional 22,391 shares during the last quarter. MAI Capital Management grew its stake in shares of Agilent Technologies by 8.1% during the third quarter. MAI Capital Management now owns 6,176 shares of the medical research company’s stock worth $473,000 after purchasing an additional 463 shares during the period. Meag Munich Ergo Kapitalanlagegesellschaft MBH increased its holdings in Agilent Technologies by 64.4% in the third quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 20,455 shares of the medical research company’s stock valued at $1,556,000 after purchasing an additional 8,012 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its holdings in Agilent Technologies by 51.5% during the third quarter. Janney Montgomery Scott LLC now owns 29,139 shares of the medical research company’s stock worth $2,233,000 after buying an additional 9,899 shares during the last quarter.
A number of brokerages recently weighed in on A. Citigroup started coverage on shares of Agilent Technologies in a research report on Monday, January 6th. They issued a “neutral” rating and a $85.00 price target on the stock. JPMorgan Chase & Co. upped their target price on shares of Agilent Technologies from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Tuesday, November 26th. HSBC raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a report on Wednesday, February 12th. Wells Fargo & Co began coverage on Agilent Technologies in a research note on Tuesday, January 7th. They set an “overweight” rating and a $100.00 price objective on the stock. Finally, Piper Sandler lifted their target price on Agilent Technologies from to and gave the stock an “overweight” rating in a report on Wednesday, February 19th. Nine analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $84.80.
Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Tuesday, February 18th. The medical research company reported $0.81 EPS for the quarter, meeting analysts’ consensus estimates of $0.81. The firm had revenue of $1.36 billion during the quarter, compared to analysts’ expectations of $1.36 billion. Agilent Technologies had a net margin of 14.59% and a return on equity of 20.49%. The company’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.76 earnings per share. On average, sell-side analysts predict that Agilent Technologies Inc will post 3.41 earnings per share for the current year.
In other Agilent Technologies news, CEO Michael R. Mcmullen sold 24,636 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $82.90, for a total value of $2,042,324.40. Following the transaction, the chief executive officer now directly owns 332,121 shares of the company’s stock, valued at approximately $27,532,830.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Dominique Grau sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $82.85, for a total value of $1,242,750.00. Following the sale, the senior vice president now owns 97,498 shares of the company’s stock, valued at approximately $8,077,709.30. The disclosure for this sale can be found here. Insiders sold a total of 65,049 shares of company stock valued at $5,499,936 over the last quarter.
Agilent Technologies Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Recommended Story: What is a balanced fund?
Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies Inc (NYSE:A).
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.